Overview


According to FutureWise analysis the market for immunoglobulins in 2023 is US$ 14.48 billion, and is expected to reach US$ 25.88 billion by 2031 at a CAGR of 7.53%.

Immunoglobulins are known as glycoproteins which are formed in the blood plasma. This, in turn, reacts to antigens that are in the body. Intravenous immunoglobulin is a blood product which is arranged from the serum and accounts to nearly 1,000 to 10,000 donors per donor. Such immunoglobulins are administered to people who are afflicted with weak immune systems. An illness such as immunodeficiency could be inherent in the body or could be attributed to the exposure of infections, by way of bodily fluids as well as chemotherapy and cancer drugs. The aging process could be another factor and can even make a person susceptible to a poor immune system.

Fast-paced and unbalanced lifestyles have led people to take to unhealthy diets and this, in turn, has caused them to develop weak immune systems. Attributes such as reduced sleeping patterns, high levels of stress, and unhealthy diets are factors which are contributing to the ever-growing presence of the illness known as immunodeficiency disorder.

Treatment of this nature is used for patients who are afflicted with antibody deficiencies. The global market for geriatric population has gained a strong foothold since there is an exponential rise in the number of hemophilic patients, technological prowess for the boost in production of intravenous immunoglobulin and positive strides in the purification methodologies. Although, stringent government guidelines with respect to the detrimental side-effects of intravenous immunoglobulin could hamper the global immunoglobulins market growth.

Going by the segmentation of component, the market for immunoglobulin is divided into IgA, IgD, IgM, IgG, IgE. The rise in the patient pool and a multitude of neurological disorders are prompting the need for speedy and dependable treatment and these are factors which have contributed significantly towards the usage of intravenous immunoglobulin in the treatment of unlabeled indications. To add to this, a hike in the research and development investments for novel goods from private and government officiated organizations alike, are expected to further augment the global immunoglobulins market size. Application-wise, the market is fragmented into Guillain-Barre syndrome, CIDP (chronic inflammatory demyelinating polyneuropathy), myasthenia gravis, immunodeficiency diseases, inflammatory myopathies, hypogammaglobinemia, thrombocytopenic purpura, specific antibody deficiency, multifocal motor neuropathy and others.

  • BDI Pharma 
  • Grifols Inc. 
  • Abeona Therapeutics 
  • Biotest AG. 
  • Baxter 
  • Octapharma 
  • China Biologic Products, Inc. 
  • Kedrion S.p.A 
  • Shire 
  • CSL Behring 

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product

  • IGG
  • IGA
  • IGE
  • IGD

By Application

  • Hypogammaglobinemia
  • Chronic Inflammatory Demyelinating polyneuropathy (CIDP)
  • Primary Immunodeficiency Diseases
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Inflammatory Myopathies
  • Specific Antibody Deficiency
  • Guillain-Barre Syndrome
  • Guillain-Barre Syndrome
  • Others

By Mode of Delivery

  • Intravenous
    • 5% Concentration
    • 10% Concentration
    • Other Concentrations
  • Subcutaneous
    • 6.5% Concentration
    • 20% Concentration
    • Other Concentrations

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the global Immunoglobulins Market By Product, By Application, By Mode Of Delivery and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
     

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Immunoglobulins Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Global Immunoglobulins Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Immunoglobulins Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Immunoglobulins Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Immunoglobulins Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. IGG
        2. IGA
        3. IGE
        4. IGD

  • 8.   Global Immunoglobulins Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hypogammaglobinemia
        2. Chronic Inflammatory Demyelinating polyneuropathy (CIDP)
        3. Primary Immunodeficiency Diseases
        4. Myasthenia Gravis
        5. Multifocal Motor Neuropathy
        6. Idiopathic Thrombocytopenic Purpura (ITP)
        7. Inflammatory Myopathies
        8. Specific Antibody Deficiency
        9. Guillain-Barre Syndrome
        10. Others

  • 9.   Global Immunoglobulins Market, By Mode of Delivery Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Intravenous
         1.1. 5% Concentration
         1.2. 10% Concentration
         1.3. Other Concentrations
        2. Subcutaneous
         2.1. 6.5% Concentration
         2.2. 20% Concentration
         2.3. Other Concentrations

  • 10.   North America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Regional Market Trends
        3. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         3.1. Brazil
         3.2. Venezuela
         3.3. Argentina
         3.4. Rest of Latin America
        4. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Switzerland
         2.9. Rest of Western Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. India
         2.5. Australia and New Zealand
         2.6. ASEAN
         2.7. South Korea
         2.8. Taiwan
         2.9. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 16.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
    •   1. BDI Pharma (US)
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Grifols Inc. (Spain)
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Abeona Therapeutics (US)
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Biotest AG. (Germany)
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Baxter (US)
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Octapharma (Switzerland)
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. China Biologic Products, Inc. (China)
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Kedrion S.p.A (US)
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Shire (Republic of Ireland)
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. CSL Behring (US)
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nation

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients